All In Biotech

Drug Trial Radar · NCT06130566

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 601 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

601

Actual

Start

Nov 8, 2023

Primary completion

Jul 23, 2025

Study completion Nov 13, 2025

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Nov 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for SC injection compared with placebo in participants with moderate to severe AD aged 12 years and older. Study details include: At the end of the treatment period, participants will have an option to enter a separate study: the blinded extension study EFC17600 (ESTUARY). For participants not entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 44 weeks including a 2 to 4-week screening, a 24-week randomized double-blind period, and a 16-week safety follow-up. For participants entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 28 weeks including a 2 to 4-week screening and a 24-week randomized double-blind period. The total treatment duration will be up to 24 weeks. The total number of visits will be up to 10 visits (or 9 visits for those entering the blinded extension study EFC17600\] (ESTUARY).

Conditions

  • Dermatitis Atopic

Interventions

  • AmlitelimabDrug

    Injection solution SC injection

  • PlaceboDrug

    Injection solution SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24Time frame: Week 24
  2. EU, EU reference countries, and Japan: Proportion of participants reaching 75% reduction from baseline in Eczema Area and Severity Index (EASI) score (EASI-75) at Week 24Time frame: Week 24
  3. US and US reference countries: Proportion of participants with vIGA-AD of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24Time frame: Week 24

Locations

148 sites in 15 countries. Site status is shown where the registry gives one.

  • Scottsdale Clinical Trials- Site Number : 8401149

    Scottsdale, Arizona

  • First OC Dermatology- Site Number : 8401025

    Fountain Valley, California

  • Center for Dermatology Clinical Research- Site Number : 8401018

    Fremont, California

  • Sunwise Clinical Research- Site Number : 8401022

    Lafayette, California

  • Carbon Health - North Hollywood - NoHo West- Site Number : 8401218

    North Hollywood, California

  • Northridge Clinical Trials - Northridge- Site Number : 8401080

    Northridge, California

  • St Jude Clinical Research- Site Number : 8401287

    Doral, Florida

  • Beth Israel Deaconess Medical Center - Fort Myers- Site Number : 8401286

    Fort Myers, Florida

  • Direct Helpers Research Center- Site Number : 8401056

    Hialeah, Florida

  • Encore Medical Research- Site Number : 8401030

    Hollywood, Florida

  • Florida International Research Center- Site Number : 8401091

    Miami, Florida

  • Miami Dermatology and Laser Research- Site Number : 8401086

    Miami, Florida

  • Clinical Neuroscience Solutions - Orlando - South Delaney Avenue- Site Number : 8401035

    Orlando, Florida

  • Cleaver Medical Group Dermatology- Site Number : 8401139

    Cumming, Georgia

  • Skin Care Physicians of Georgia - Macon- Site Number : 8401034

    Macon, Georgia

  • Javara Research - Thomasville- Site Number : 8401189

    Thomasville, Georgia

  • Rophe Adult & Pediatric Medicine- Site Number : 8401289

    Union City, Georgia

  • Skin Sciences- Site Number : 8401039

    Louisville, Kentucky

  • MedPharmics - Covington- Site Number : 8401137

    Covington, Louisiana

  • MedPharmics - Lafeyette- Site Number : 8401152

    Lafayette, Louisiana

  • Massachusetts General Hospital- Site Number : 8401192

    Boston, Massachusetts

  • Metro Boston Clinical Partners- Site Number : 8401128

    Needham, Massachusetts

  • Revival Research - Doral- Site Number : 8401012

    Dearborn, Michigan

  • Henry Ford Hospital- Site Number : 8401044

    Detroit, Michigan

  • SKY Integrative Medical Center/SKYCRNG - Ridgeland- Site Number : 8401058

    Ridgeland, Mississippi

  • MediSearch Clinical Trials- Site Number : 8401140

    Saint Joseph, Missouri

  • Somnos Clinical Research- Site Number : 8401203

    Lincoln, Nebraska

  • Universal Dermatology- Site Number : 8401224

    Fairport, New York

  • Sadick Research Group - New York - Park Avenue- Site Number : 8401050

    New York, New York

  • CHEAR Center- Site Number : 8401123

    The Bronx, New York

  • Onsite Clinical Solutions - Charlotte - Blakeney Park Drive- Site Number : 8401124

    Charlotte, North Carolina

  • Oregon Medical Research Center- Site Number : 8401017

    Portland, Oregon

  • Vial Health - DermDox Dermatology- Site Number : 8401031

    Camp Hill, Pennsylvania

  • Paddington Testing Company- Site Number : 8401041

    Philadelphia, Pennsylvania

  • Clinical Research of Philadelphia- Site Number : 8401193

    Philadelphia, Pennsylvania

  • Tribe Clinical Research - 525 Verdae Boulevard- Site Number : 8401225

    Greenville, South Carolina

  • Dermatology Treatment and Research Center- Site Number : 8401164

    Dallas, Texas

  • Skin Specialist of Addison- Site Number : 8401208

    Dallas, Texas

  • Texas Dermatology and Laser Specialists- Site Number : 8401131

    San Antonio, Texas

  • Stryde Research - Epiphany Dermatology- Site Number : 8401185

    Southlake, Texas

Showing 40 of 148 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.